0001127602-17-016857.txt : 20170504 0001127602-17-016857.hdr.sgml : 20170504 20170504161601 ACCESSION NUMBER: 0001127602-17-016857 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170502 FILED AS OF DATE: 20170504 DATE AS OF CHANGE: 20170504 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOGEN INC. CENTRAL INDEX KEY: 0000875045 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330112644 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 225 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 7814642000 MAIL ADDRESS: STREET 1: 225 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: BIOGEN IDEC INC. DATE OF NAME CHANGE: 20070427 FORMER COMPANY: FORMER CONFORMED NAME: BIOGEN IDEC INC DATE OF NAME CHANGE: 20031112 FORMER COMPANY: FORMER CONFORMED NAME: IDEC PHARMACEUTICALS CORP / DE DATE OF NAME CHANGE: 19970530 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Vounatsos Michel CENTRAL INDEX KEY: 0001672709 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19311 FILM NUMBER: 17814131 MAIL ADDRESS: STREET 1: BIOGEN INC. STREET 2: 225 BINNEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2017-05-02 0000875045 BIOGEN INC. BIIB 0001672709 Vounatsos Michel BIOGEN INC. 225 BINNEY ST. CAMBRIDGE MA 02142 1 1 Chief Executive Officer Common Stock 2017-05-02 4 M 0 1736 0 A 4663.458 D Common Stock 2017-05-02 4 F 0 564 271.34 D 4099.458 D Restricted Stock Unit 0 2017-05-02 4 M 0 1736 0 D 2019-05-02 Common Stock 1736 8004 D Restricted Stock Unit 0 2017-05-02 4 J 0 1508 0 D 2019-05-02 Common Stock 1508 6496 D This award was previously reported as covering 9,520 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ, Inc. on February 1, 2017. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. Suzanne Murray, Attorney in Fact for Michel Vounatsos 2017-05-04